Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations

Pain

Volumn 153, Issue 12, 2012, Pages 2315-2324

  Comer, Sandra D ^a   Zacny, James P ^b   Dworkin, Robert H ^c   Turk, Dennis C ^d   Bigelow, George E ^e   Foltin, Richard W ^a   Jasinski, Donald R ^e   Sellers, Edward M ^f   Adams, Edgar H ^g   Balster, Robert ^h   Burke, Laurie B ⁱ   Cerny, Igor ⁱ   Colucci, Robert D ^j   Cone, Edward ^e   Cowan, Penney ^k   Farrar, John T ^l   David Haddox, J ^m   Haythornthwaite, Jennifer A ^e   Hertz, Sharon ⁱ   Jay, Gary W ⁿ   Johanson, Chris Ellyn ^o   Junor, Roderick ^p   Katz, Nathaniel P ^q,r   Klein, Michael ⁱ   Kopecky, Ernest A ^s   Leiderman, Deborah B ^t   McDermott, Michael P ^c,u   O'Brien, Charles ^v   O'Connor, Alec B ^u   Palmer, Pamela P ^w   Raja, Srinivasa N ^e   Rappaport, Bob A ⁱ   Rauschkolb, Christine ^x   Rowbotham, Michael C ^y   Sampaio, Cristina ^z   Setnik, Beatrice ^aa   Sokolowska, Marta ^ab   Stauffer, Joseph W ^ac   Walsh, Sharon L ^ad   more..

^a Columbia University ^*  (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DecisionLine Clinical Research Corporation   (Canada)

^g Dept of Stat and Clin Programming   (United States)

^h VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j United States Food and Drug Administration ^*  (United States)

^k American Chronic Pain Association   (United States)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m PURDUE PHARMA L P   (United States)

ⁿ PFIZER INC   (United States)

^o WAYNE STATE UNIVERSITY   (United States)

^p EISAI INC   (United States)

^q Analgesic Research   (United States)

^r TUFTS UNIVERSITY   (United States)

^s ENDO PHARMACEUTICALS INC   (United States)

^t CNS Drug Consulting LLC   (United States)

^u UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^v UNIVERSITY OF PENNSYLVANIA   (United States)

^w AcelRx Pharmaceuticals Inc   (United States)

^x JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^y CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^z INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^aa King Pharmaceuticals Inc   (United States)

^ab GRÜNENTHAL GMBH   (Germany)

^ac DURECT Corporation   (United States)

^ad UNIVERSITY OF KENTUCKY   (United States)

more..

Author keywords

Abuse; Abuse liability; Abuse potential; Opioid analgesics; Opioids

Indexed keywords

AMPHETAMINE; ANALGESIC AGENT; CHLORPROMAZINE; COCAINE; DIAMORPHINE; LYSERGIDE; MORPHINE; OPIATE; PENTOBARBITAL; PLACEBO;

BLOOD PRESSURE MONITORING; CHRONIC PAIN; COGNITION; CONSENSUS; DRUG IDENTIFICATION; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; GOVERNMENT; HEART RATE; HUMAN; LABORATORY TEST; LEGAL LIABILITY; MOOD; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT ADVOCACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RESPIRATION DEPRESSION; REVIEW; STANDARDIZATION; VISUAL ANALOG SCALE;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; HUMANS; INTERNATIONALITY; NEUROLOGY; OPIOID-RELATED DISORDERS; OUTCOME ASSESSMENT (HEALTH CARE); PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84868525984     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2012.07.035     Document Type: Review

References (71)

1. N.A. Ator, and R.R. Griffiths Principles of drug abuse liability assessment in laboratory animals Drug Alcohol Depend 70 2003 S55 S72
2. A.D. Baddeley A three-minute reasoning test based on grammatical transformation Psychon Sci 10 1968 341 342
3. R.L. Balster, and G.E. Bigelow Guidelines and methodological reviews concerning drug abuse liability assessment Drug Alcohol Depend 70 2003 S13 S40
4. G.E. Bigelow Human drug abuse liability assessment: opioids and analgesics Br J Addict 86 1991 1615 1623
5. C.J. Boyd, S.E. McCabe, J.A. Cranford, and A. Young Adolescents' motivations to abuse prescription medications Pediatrics 118 2006 2472 2480
6. U.E. Busto, L.A. Zawertailo, H.L. Kaplan, and E.M. Sellers Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing Can J Clin Pharmacol 6 1999 103 110
7. L.P. Carter, and R.R. Griffiths Principles of laboratory assessment of drug abuse liability and implications for clinical development Drug Alcohol Depend 105 2009 S14 S25
8. R. Chou, G.J. Fanciullo, P.G. Fine, C. Miaskowski, S.D. Passik, and R.K. Portenoy Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline J Pain 10 2009 131 146
9. S.D. Comer, J.B. Ashworth, R.W. Foltin, C.E. Johanson, J.P. Zacny, and S.L. Walsh The role of human drug self-administration procedures in the development of medications Drug Alcohol Depend 96 2008 1 15
10. S.D. Comer, E.D. Collins, and M.W. Fischman Choice between money and intranasal heroin in morphine-maintained humans Behav Pharmacol 8 1997 677 690
11. S.D. Comer, M.A. Sullivan, S.K. Vosburg, W.J. Kowalczyk, and J. Houser Abuse liability of oxycodone as a function of pain and drug use history Drug Alcohol Depend 109 2010 130 138
12. S.D. Comer, M.A. Sullivan, R.A. Whittington, S.K. Vosburg, and W.J. Kowalczyk Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers Neuropsychopharmacology 33 2008 1179 1191
13. R.H. Dworkin, D.C. Turk, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, N.P. Katz, R.D. Kerns, G. Stucki, R.R. Allen, N. Bellamy, D.B. Carr, J. Chandler, P. Cowan, R. Dionne, B.S. Galer, S. Hertz, A.R. Jadad, L.D. Kramer, D.C. Manning, S. Martin, C.G. McCormick, M.P. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, W. Robbins, J.P. Robinson, M. Rothman, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, J. Wernicke, and J. Witter Core outcome measures for chronic pain clinical trials: IMMPACT recommendations PAIN® 113 2005 9 19
14. R.H. Dworkin, D.C. Turk, S. Peirce-Sandner, R. Baron, N. Bellamy, L.B. Burke, A. Chappell, K. Chartier, C.S. Cleeland, A. Costello, P. Cowan, R. Dimitrova, S. Ellenberg, J.T. Farrar, J.A. French, I. Gilron, S. Hertz, A.R. Jadad, G.W. Jay, J. Kalliomaki, N.P. Katz, R.D. Kerns, D.C. Manning, M.P. McDermott, P.J. McGrath, A. Narayana, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, B.B. Reeve, T. Rhodes, C. Sampaio, D.M. Simpson, J.W. Stauffer, G. Stucki, J. Tobias, R.E. White, and J. Witter Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations PAIN® 149 2010 177 193
15. S.M. Evans, F.R. Funderburk, and R.R. Griffiths Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability J Pharmacol Exp Ther 255 1990 1246 1255
16. M.W. Fischman, and C.E. Johanson Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers Behav Pharmacol 9 1998 479 498
17. Food and Drug Administration USDHHS. Center for drug evaluation and research. Guidance for industry: assessment of abuse potential of drugs, 2010. Available at: < http://www.fda.gov/cder/guidance/index.htm >.
18. H.F. Fraser, and H. Isbell Addiction liabilities of morphinan, 6-methyldihydromorphine and dihydrocodeinone J Pharmacol Exp Ther 100 1950 128 135
19. H.F. Fraser, and D.R. Jasinski The assessment of the abuse potentiality of sedative/hypnotics (depressants) (methods used in animals and man) W.R. Martin, Drug addiction I: morphine, sedative-hypnotic and alcohol dependence. Handbook of experimental pharmacology 1977 Springer-Verlag Heidelberg 589 612
20. H.F. Fraser, T.L. Nash, G.D. Vanhorn, and H. Isbell Use of miotic effect in evaluating analgesic drugs in man Arch Int Pharmacodyn Ther 98 1954 443 451
21. H.F. Fraser, G.D. Van Horn, W.R. Martin, A.B. Wolbach, and H. Isbell Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) A short-term "direct" addiction test J Pharmacol Exp Ther 133 1961 371 387
22. R.R. Griffiths, G.E. Bigelow, and N.A. Ator Principles of initial experimental drug abuse liability assessment in humans Drug Alcohol Depend 70 2003 S41 S54
23. C.A. Haertzen Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI) Psychol Rep 18 1966 163 194
24. C.A. Haertzen, H.E. Hill, and R.E. Belleville Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs Psychopharmacologia 4 1963 155 166
25. M. Haney Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls Addict Biol 14 2009 9 21
26. J.G. Hannington-Kiff Measurement of recovery from outpatient general anaesthesia with a simple ocular test Br Med J 3 1970 132 135
27. S.T. Higgins, K.L. Preston, E.J. Cone, J.E. Henningfield, and J.H. Jaffe Supersensitivity to naloxone following acute morphine pretreatment in humans: behavioral, hormonal and physiological effects Drug Alcohol Depend 30 1992 13 26
28. H.E. Hill, C.A. Haertzen, A.B. Wolbach Jr., and E.J. Miner The addiction research center inventory: Appendix. I. Items comprising empirical scales for seven drugs. II. Items which do not differentiate placebo from any drug condition Psychopharmacologia 4 1963 184 205
29. H.E. Hill, C.A. Haertzen, A.B. Wolbach Jr., and E.J. Miner The addiction research center inventory: standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine Psychopharmacologia 4 1963 167 183
30. H. Isbell Methods and results of studying experimental human addiction to the newer synthetic analgesics Ann NY Acad Sci 51 1948 108 122
31. D.R. Jasinski Assessment of the abuse potentiality of morphine-like drugs methods used in man W.R. Martin, Drug addiction Morphine sedative-hypnotic and alcohol dependence Handbook of experimental pharmacology 1977 Springer-Verlag Heidelberg 197 258
32. D.R. Jasinski History of abuse liability testing in humans Br J Addict 86 1991 1559 1562
33. D.R. Jasinski, and P.A. Mansky Evaluation of nalbuphine for abuse potential Clin Pharmacol Ther 13 1972 78 90
34. D.R. Jasinski, W.R. Martin, and R.D. Hoeldtke Effects of short- and long-term administration of pentazocine in man Clin Pharmacol Ther 11 1970 385 403
35. C.E. Johanson Assessing the reinforcing properties of drugs NIDA Res Monogr 95 1989 135 145
36. C.E. Johanson Behavioral pharmacology, drug abuse, and the future Behav Pharmacol 1 1990 385 393
37. C.E. Johanson, and H. de Wit The use of choice procedures for assessing the reinforcing properties of drugs in humans NIDA Res Monogr 92 1989 171 210
38. H.L. Kaplan, U.E. Busto, G.J. Baylon, S.W. Cheung, S.V. Otton, G. Somer, and E.M. Sellers Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability J Pharmacol Exp Ther 281 1997 103 108
39. N. Katz Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 10 2008 11 18
40. B. Lalovic, E. Kharasch, C. Hoffer, L. Risler, L.Y. Liu-Chen, and D.D. Shen Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites Clin Pharmacol Ther 79 2006 461 479
41. R.J. Lamb, K.L. Preston, C.W. Schindler, R.A. Meisch, F. Davis, J.L. Katz, J.E. Henningfield, and S.R. Goldberg The reinforcing and subjective effects of morphine in post-addicts: a dose-response study J Pharmacol Exp Ther 259 1991 1165 1173
42. L. Lasagna, J.M. Von Felsinger, and H.K. Beecher Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts J Am Med Assoc 157 1955 1006 1020
43. B.A. Martell, P.G. O'Connor, R.D. Kerns, W.C. Becker, K.H. Morales, T.R. Kosten, and D.A. Fiellin Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction Ann Intern Med 146 2007 116 127
44. W.R. Martin, J.W. Sloan, J.D. Sapira, and D.R. Jasinski Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man Clin Pharmacol Ther 12 1971 245 258
45. S.E. McCabe, J.A. Cranford, C.J. Boyd, and C.J. Teter Motives, diversion and routes of administration associated with nonmedical use of prescription opioids Addict Behav 32 2007 562 575
46. S. McColl, and E.M. Sellers Research design strategies to evaluate the impact of formulations on abuse liability Drug Alcohol Depend 83 2006 S52 S62
47. D.R. McLeod, R.R. Griffiths, G. Bigelow, and J. Yingling An automated version of the Digit Symbol Substitution Test (DSST) Behav Res Methods Instrum 14 1982 463 466
48. N.M. Petry, W.K. Bickel, J. Huddleston, E. Tzanis, and G.J. Badger A comparison of subjective, psychomotor and physiological effects of a novel muscarinic analgesic, LY297802 tartrate, and oral morphine in occasional drug users Drug Alcohol Depend 50 1998 129 136
49. K.L. Preston, G.E. Bigelow, W.K. Bickel, and I.A. Liebson Drug discrimination in human postaddicts: agonist-antagonist opioids J Pharmacol Exp Ther 250 1989 184 196
50. K.L. Preston, G.E. Bigelow, and I.A. Liebson Comparative evaluation of morphine, pentazocine and ciramadol in postaddicts J Pharmacol Exp Ther 240 1987 900 910
51. K.L. Preston, I.A. Liebson, and G.E. Bigelow Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination J Pharmacol Exp Ther 261 1992 62 71
52. K.L. Preston, and S.L. Walsh Evaluating abuse liability: methods and predictive value Drug abuse handbook 1998 CRC Press Boca Raton, FL 276 306
53. J.D. Roache Performance and physiological measures in abuse liability evaluation Br J Addict 86 1991 1595 1600
54. SAMHSA. Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-41, HHS Publication No. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
55. K.A. Schoedel, S. McMorn, B. Chakraborty, S.L. Potts, K. Zerbe, and E.M. Sellers Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users J Opioid Manag 7 2011 179 192
56. K.A. Schoedel, S. McMorn, B. Chakraborty, K. Zerbe, and E.M. Sellers Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone Pain Physician 13 2010 561 573
57. M.J. Shram, G. Sathyan, S. Khanna, I.C. Tudor, R. Nath, J. Thipphawong, and E.M. Sellers Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone J Clin Psychopharmacol 30 2010 25 33
58. E. Simonson, and J. Brozek Flicker fusion frequency; background and applications Physiol Rev 32 1952 349 378
59. R. Spiga, D.B. Huang, R.A. Meisch, and J. Grabowski Human methadone self-administration: effects of diazepam pretreatment Exp Clin Psychopharmacol 9 2001 40 46
60. W.W. Stoops, K.W. Hatton, M.R. Lofwall, P.A. Nuzzo, and S.L. Walsh Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies Psychopharmacology (Berl) 212 2010 193 203
61. D.A. Tompkins, R.K. Lanier, J.A. Harrison, E.C. Strain, and G.E. Bigelow Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone Psychopharmacology (Berl) 210 2010 471 480
62. D.C. Turk, R.H. Dworkin, R.R. Allen, N. Bellamy, N. Brandenburg, D.B. Carr, C. Cleeland, R. Dionne, J.T. Farrar, B.S. Galer, D.J. Hewitt, A.R. Jadad, N.P. Katz, L.D. Kramer, D.C. Manning, C.G. McCormick, M.P. McDermott, P. McGrath, S. Quessy, B.A. Rappaport, J.P. Robinson, M.A. Royal, L. Simon, J.W. Stauffer, W. Stein, J. Tollett, and J. Witter Core outcome domains for chronic pain clinical trials: IMMPACT recommendations PAIN® 106 2003 337 345
63. D.C. Turk, R.H. Dworkin, M.P. McDermott, N. Bellamy, L.B. Burke, J.M. Chandler, C.S. Cleeland, P. Cowan, R. Dimitrova, J.T. Farrar, S. Hertz, J.F. Heyse, S. Iyengar, A.R. Jadad, G.W. Jay, J.A. Jermano, N.P. Katz, D.C. Manning, S. Martin, M.B. Max, P. McGrath, H.J. McQuay, S. Quessy, B.A. Rappaport, D.A. Revicki, M. Rothman, J.W. Stauffer, O. Svensson, R.E. White, and J. Witter Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Initiative on methods, measurement, and pain assessment in clinical trials PAIN® 139 2008 485 493
64. S.L. Walsh, P.A. Nuzzo, M.R. Lofwall, and J.R. Holtman Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers Drug Alcohol Depend 98 2008 191 202
65. S.L. Walsh, E.C. Strain, M.E. Abreu, and G.E. Bigelow Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans Psychopharmacology (Berl) 157 2001 151 162
66. L. Webster Update on abuse-resistant and abuse-deterrent approaches to opioid formulations Pain Med 10 2009 S124 S133
67. L.R. Webster, F.K. Johnson, J. Stauffer, B. Setnik, and S. Ciric Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users Drugs Res Des 11 2011 259 275
68. D. Wechsler The measurement and appraisal of adult intelligence 1958 Williams & Wilkins Baltimore
69. J.P. Zacny, and M. Drum Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex Drug Alcohol Depend 107 2010 209 214
70. J.P. Zacny, and S. Gutierrez Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers Psychopharmacology (Berl) 170 2003 242 254
71. J.P. Zacny, and S. Gutierrez Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers Drug Alcohol Depend 101 2009 107 114